Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2NIH 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm Metastasis 3Biliary Tract Neoplasms 2Thyroid Cancer, Papillary 1Rectal Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Bile Duct Neoplasms 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 2Endoscopy, Digestive System 2Endoscopy 2Biopsy 2Aspirin 2polyphenon E 1obeticholic acid 1Ursodeoxycholic Acid 1Radiofrequency Ablation 1Metformin 1Itraconazole 1Genetic Linkage 1Gastroscopy 1Esomeprazole 1Erlotinib Hydrochloride 1Comparative Genomic Hybridization 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Barrett Esophagus × Radiofrequency Ablation × Clear all
NCT06732388 2026-05-13

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
64 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡